Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178415
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Formiga Pérez, Francesc | - |
dc.contributor.author | Garcia Pavia, Pablo | - |
dc.contributor.author | Martín Sánchez, Francisco Javier | - |
dc.contributor.author | Navarro-Ruiz, Andrés | - |
dc.contributor.author | Rubio-Terrés, Carlos | - |
dc.contributor.author | Peral, Carmen | - |
dc.contributor.author | Tarilonte, Patricia | - |
dc.contributor.author | López-Ibáñez de Aldecoa, Alejandra | - |
dc.contributor.author | Rubio-Rodríguez, Darío | - |
dc.date.accessioned | 2021-06-15T13:11:21Z | - |
dc.date.available | 2021-06-15T13:11:21Z | - |
dc.date.issued | 2011-06-11 | - |
dc.identifier.issn | 1473-7167 | - |
dc.identifier.uri | http://hdl.handle.net/2445/178415 | - |
dc.description.abstract | Objective: to estimate the health and economic impact of the reduction in mortality and cardiovascular hospitalizations, associated with correct diagnosis of cardiac transthyretin amyloidosis (ATTR-CM), from the Spanish National Health System (NHS) perspective. Methods: a costs and effects analysis were performed (probabilistic Markov model) with time horizons between 1 and 15 years, comparing the correct diagnosis of ATTR-CM versus the non-diagnosis. Transition probabilities were obtained from the ATTR-ACT study (placebo arm) and from the literature. Costs and healthcare resources were obtained from Spanish sources ( 2019) and from a panel of Spanish clinical experts. Results: after 1, 5, 10 and 15 years, the diagnosis of ATTR-CM would generate a gain of 0.031 (95%CI 0.025; 0.038); 0.387 (95%CI 0.329; 0.435); 0.754 (95%CI 0.678; 0.781) and 0.944 (95%CI 0.905; 0.983) life years per patient, respectively, with savings of 212 (95%CI -632; 633), 2,289 (95%CI 2,250; 2,517), 2,859 (95%CI 2,584; 3,149) and 2,906 (95%CI 2,669; 3,450) per patient, respectively, versus the non-diagnosis. Conclusions: just by correctly diagnosing ATTR-CM, years of life would be gained, cardiovascular hospitalizations would be avoided, and savings would be generated for the NHS, compared to the non-diagnosis of the disease. | - |
dc.format.extent | 7 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1080/14737167.2021.1933948 | - |
dc.relation.ispartof | Expert Review of Pharmacoeconomics & Outcomes Research, 2011, vol. 11, p. 1-7 | - |
dc.relation.uri | https://doi.org/10.1080/14737167.2021.1933948 | - |
dc.rights | cc by nc nd (c) Formiga Pérez, Francesc et al, 2011 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Amiloïdosi | - |
dc.subject.classification | Diagnòstic | - |
dc.subject.classification | Espanya | - |
dc.subject.other | Amyloidosis | - |
dc.subject.other | Diagnosis | - |
dc.subject.other | Spain | - |
dc.title | Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 712753 | - |
dc.date.updated | 2021-06-15T13:11:21Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34047214 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
712753.pdf | 1 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License